- Home
- CRNX vs LBTYA Comparison
CRNX vs LBTYA Comparison
Compare CRNX & LBTYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRNX | LBTYA |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | Bermuda |
| Employees | N/A | 6820 |
| Industry | Biotechnology: Pharmaceutical Preparations | Cable & Other Pay Television Services |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.3B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRNX | LBTYA |
|---|---|---|
| Price | $40.94 | $12.60 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 5 |
| Target Price | ★ $76.63 | $13.72 |
| AVG Volume (30 Days) | 1.0M | ★ 2.1M |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,039,000.00 | N/A |
| Revenue This Year | $720.10 | $15.41 |
| Revenue Next Year | $184.67 | $1.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.83 | $9.19 |
| 52 Week High | $57.99 | $13.52 |
Technical Indicators
Market Signals| Indicator | CRNX | LBTYA |
|---|---|---|
| Relative Strength Index (RSI) | 59.94 | 57.08 |
| Support Level | $39.35 | $11.45 |
| Resistance Level | $45.32 | $12.98 |
| Average True Range (ATR) | 1.47 | 0.31 |
| MACD | 0.61 | 0.03 |
| Stochastic Oscillator | 95.81 | 82.32 |
Price Performance
Historical ComparisonAbout CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
About LBTYA Liberty Global Ltd.
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.